B

• Results from Operations for first quarter 2026 versus first quarter 2025:
  • Revenue: $3.54 billion vs. $3.35 billion, up 5.8%
  • Diluted EPS: $3.35 vs. $2.52, up 32.8%
  • Adjusted EPS: $4.25 vs. $3.84, up 10.6%
• Raised Full-Year Enterprise Revenue and Adjusted EPS guidance:
  • Revenue guidance of 5.0% to 6.1%; up 20 basis points at the midpoint
  • Adjusted EPS range of $17.70 to $18.35; up 13 cents at the midpoint
• Advanced leadership in specialty and companion diagnostics and expanded strategic health systems collaborations
• Collaborated with Optum.ai to enhance patient and provider experience

BURLINGTON, N.C., April 30, 2026 /PRNewswire/ — Labcorp Holdings Inc (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the first quarter ended March 31, 2026 and updated full-year guidance.

“Labcorp delivered another quarter of strong results, with robust growth and double-digit Adjusted EPS growth driven by continued momentum across our Diagnostics and Central Laboratory businesses,” said Adam Schechter, Chairman and CEO of Labcorp. “Health systems, providers, consumers, and biopharmaceutical customers are increasingly turning to Labcorp as their partner of choice for their complex, innovative testing needs. Our investments in advanced technologies, including robotics and AI, are improving the customer experience and transforming the way we operate. Driven by continued progress across our strategic priorities, we are raising our full year Adjusted EPS guidance to $18.03 at the midpoint of the range, an increase of $0.13.”

Labcorp continues to advance its strategic priorities:

Be a partner of choice for health systems and regional and local laboratories:

• Announced a nationwide strategic collaboration with Children’s Hospital of Philadelphia (CHOP) to expand access to cutting-edge diagnostics for pediatric patients.

• Completed the acquisition of select assets of Crouse Health’s Laboratory Alliance of Central New York and executed an agreement with Crouse Health to manage their inpatient labs.

Lead in specialty testing:

• Announced a collaboration with Illumina to expand access to advanced genomic testing in oncology to deliver more precise biomarker insights.

• Expanded nationwide access to the first FDA-approved companion diagnostic that helps identify patients with platinum‑resistant ovarian cancer who may benefit from Merck’s KEYTRUDA® and KEYTRUDA QLEX™.

• Launched the Labcorp Fentanyl Visual Urine Test, an FDA‑cleared rapid screening test that delivers results in just 10 minutes and assesses possible fentanyl exposure for up to 48 hours.

Shape our future through technology and innovation:

• Launched an AI-powered, real-world data platform with Amazon Web Services (AWS) and Datavant to accelerate Alzheimer’s research.

• Expanded a collaboration with PathAI to deploy AISight® Dx, an FDA-cleared digital pathology platform.

• Announced a collaboration with Optum.ai to apply AI capabilities to streamline laboratory operations, improve efficiency, and enhance the patient and provider experience.

Drive personalized health solutions:

• Grew Consumer Health and expanded the Labcorp OnDemand test portfolio with new tests for insulin resistance and pancreatic function, as well as customizable men’s and women’s health tests.

• In May, the company will launch MyLabcorp, a secure, AI-powered mobile app that brings an individual’s test results and health data together with clinical guidance to help consumers better understand their test results.

Labcorp also remains committed to a disciplined allocation of capital. In the first quarter of 2026, the company invested $202.2 million in acquisitions, repurchased $98.0 million of stock, and paid out $61.2 million in dividends. On April 9, 2026, the company announced a quarterly cash dividend of $0.72 per share of common stock, payable on June 11, 2026, to stockholders of record at the close of business on May 29, 2026.

Capital Allocation Summary

• At the end of the quarter, Labcorp’s cash and cash equivalents balance was $981.1 million and total debt was $6.33 billion. These higher cash and debt balances are due to the pre-funding of maturing debt.

• During the quarter, the company invested $202.2 million in acquisitions, repurchased $98.0 million of stock, and paid out $61.2 million in dividends.

Guidance for 2026

Labcorp is updating 2026 full year guidance to reflect its first quarter performance and full year outlook. The following guidance assumes foreign exchange rates effective as of March 31, 2026. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases, and dividends.

Use of Adjusted Measures

The company has provided in this press release and accompanying tables “adjusted” financial information that has not been prepared in accordance with GAAP, including adjusted net income, adjusted EPS (or adjusted net income per share), adjusted operating income, adjusted operating margin, free cash flow, and certain segment information. The company believes these adjusted measures are useful to investors as a supplement to, but not as a substitute for, GAAP measures, in evaluating the company’s operational performance. The company further believes that the use of these non-GAAP financial measures provides an additional tool for investors in evaluating operating results and trends, and growth and shareholder returns, as well as in comparing the company’s financial results with the financial results of other companies. However, the company notes that th